En español
NIDA

How Antibodies Help Cut Cocaine Abuse Description

line graph shows the progression of reduced cocaine abuse among users with high levels of the antibody vaccine, low levels of the vaccine, and the placebo Antibodies Help Cut Cocaine Abuse: As the study progressed from week 1 to week 16, all patients reduced cocaine abuse—but vaccine recipients did so more quickly and to a greater extent. During the vaccination period, those who produced high levels of cocaine-blocking immunoglobulin G (IgG) antibodies (greater than or equal to 43 μg/mL) submitted a greater percentage of cocaine-free urine samples than participants who had a lesser response to the vaccine or those in the placebo group.

This line graph, titled "How Antibodies Help Cut Cocaine Abuse," displays the time since first treatment (in weeks) on the horizontal axis and the percentage of cocaine-free urine samples on the vertical axis. There are three lines on the graph: the line with blue diamonds representing an active cocaine vaccine with high lgG levels (≥43 μg/mL), the line with red squares representing an active cocaine vaccine with low lgG levels (<43 μg/mL), and the line with yellow triangles representing a placebo.

At 1 week since first treatment, the active cocaine vaccine with high lgG levels (≥43 μg/mL) had 17% of cocaine-free urine samples, the active cocaine vaccine with low lgG levels (<43 μg/mL) had 23% of cocaine-free urine samples, and the placebo had 29% of cocaine-free urine samples.

At 2 weeks since first treatment, the active cocaine vaccine with high lgG levels (≥43 μg/mL) had 20% of cocaine-free urine samples, the active cocaine vaccine with low lgG levels (<43 μg/mL) had 27% of cocaine-free urine samples, and the placebo had 30% of cocaine-free urine samples.

At 3 weeks since first treatment, the active cocaine vaccine with high lgG levels (≥43 μg/mL) had 25% of cocaine-free urine samples, the active cocaine vaccine with low lgG levels (<43 μg/mL) had 30% of cocaine-free urine samples, and the placebo had 32% of cocaine-free urine samples.

At 4 weeks since first treatment, the active cocaine vaccine with high lgG levels (≥43 μg/mL) had 32% of cocaine-free urine samples, the active cocaine vaccine with low lgG levels (<43 μg/mL) had 32% of cocaine-free urine samples, and the placebo had 32% of cocaine-free urine samples.

At 5 weeks since first treatment, the active cocaine vaccine with high lgG levels (≥43 μg/mL) had 32% of cocaine-free urine samples, the active cocaine vaccine with low lgG levels (<43 μg/mL) had 32% of cocaine-free urine samples, and the placebo had 40% of cocaine-free urine samples.

At 6 weeks since first treatment, the active cocaine vaccine with high lgG levels (≥43 μg/mL) had 34% of cocaine-free urine samples, the active cocaine vaccine with low lgG levels (<43 μg/mL) had 35% of cocaine-free urine samples, and the placebo had 36% of cocaine-free urine samples.

At 7 weeks since first treatment, the active cocaine vaccine with high lgG levels (≥43 μg/mL) had 37% of cocaine-free urine samples, the active cocaine vaccine with low lgG levels (<43 μg/mL) had 38% of cocaine-free urine samples, and the placebo had 35% of cocaine-free urine samples.

At 8 weeks since first treatment, the active cocaine vaccine with high lgG levels (≥43 μg/mL) had 33% of cocaine-free urine samples, the active cocaine vaccine with low lgG levels (<43 μg/mL) had 40% of cocaine-free urine samples, and the placebo had 34% of cocaine-free urine samples.

At 9 weeks since first treatment, the active cocaine vaccine with high lgG levels (≥43 μg/mL) had 44% of cocaine-free urine samples, the active cocaine vaccine with low lgG levels (<43 μg/mL) had 35% of cocaine-free urine samples, and the placebo had 32% of cocaine-free urine samples.

At 10 weeks since first treatment, the active cocaine vaccine with high lgG levels (≥43 μg/mL) had 45% of cocaine-free urine samples, the active cocaine vaccine with low lgG levels (<43 μg/mL) had 37% of cocaine-free urine samples, and the placebo had 34% of cocaine-free urine samples.

At 11 weeks since first treatment, the active cocaine vaccine with high lgG levels (≥43 μg/mL) had 44% of cocaine-free urine samples, the active cocaine vaccine with low lgG levels (<43 μg/mL) had 36% of cocaine-free urine samples, and the placebo had 31% of cocaine-free urine samples.

At 12 weeks since first treatment, the active cocaine vaccine with high lgG levels (≥43 μg/mL) had 42% of cocaine-free urine samples, the active cocaine vaccine with low lgG levels (<43 μg/mL) had 37% of cocaine-free urine samples, and the placebo had 35% of cocaine-free urine samples.

At 13 weeks since first treatment, the active cocaine vaccine with high lgG levels (≥43 μg/mL) had 45% of cocaine-free urine samples, the active cocaine vaccine with low lgG levels (<43 μg/mL) had 36% of cocaine-free urine samples, and the placebo had 39% of cocaine-free urine samples.

At 14 weeks since first treatment, the active cocaine vaccine with high lgG levels (≥43 μg/mL) had 45% of cocaine-free urine samples, the active cocaine vaccine with low lgG levels (<43 μg/mL) had 38% of cocaine-free urine samples, and the placebo had 38% of cocaine-free urine samples.

At 15 weeks since first treatment, the active cocaine vaccine with high lgG levels (≥43 μg/mL) had 46% of cocaine-free urine samples, the active cocaine vaccine with low lgG levels (<43 μg/mL) had 33% of cocaine-free urine samples, and the placebo had 38% of cocaine-free urine samples.

At 16 weeks since first treatment, the active cocaine vaccine with high lgG levels (≥43 μg/mL) had 47% of cocaine-free urine samples, the active cocaine vaccine with low lgG levels (<43 μg/mL) had 34% of cocaine-free urine samples, and the placebo had 41% of cocaine-free urine samples.

At 17 weeks since first treatment, the active cocaine vaccine with high lgG levels (≥43 μg/mL) had 35% of cocaine-free urine samples, the active cocaine vaccine with low lgG levels (<43 μg/mL) had 31% of cocaine-free urine samples, and the placebo had 43% of cocaine-free urine samples.

At 18 weeks since first treatment, the active cocaine vaccine with high lgG levels (≥43 μg/mL) had 40% of cocaine-free urine samples, the active cocaine vaccine with low lgG levels (<43 μg/mL) had 32% of cocaine-free urine samples, and the placebo had 40% of cocaine-free urine samples.

At 19 weeks since first treatment, the active cocaine vaccine with high lgG levels (≥43 μg/mL) had 36% of cocaine-free urine samples, the active cocaine vaccine with low lgG levels (<43 μg/mL) had 30% of cocaine-free urine samples, and the placebo had 35% of cocaine-free urine samples.

At 20 weeks since first treatment, the active cocaine vaccine with high lgG levels (≥43 μg/mL) had 38% of cocaine-free urine samples, the active cocaine vaccine with low lgG levels (<43 μg/mL) had 30% of cocaine-free urine samples, and the placebo had 36% of cocaine-free urine samples.

Go Back To: Cocaine Vaccine Helps Some Reduce Drug Abuse